HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 earnings call transcript

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026 Halozyme Therapeutics, Inc.
Targeted Oncology

FAQ: Using Minimal Residual Disease (MRD) in Multiple Myeloma Clinical Trials

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...
CURE

FDA Accepts Application for Iberdomide in Multiple Myeloma Treatment

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

Halozyme Therapeutics Q4 Earnings Call Highlights

Halozyme Therapeutics (NASDAQ:HALO) executives highlighted what they described as a “significant and value-creating” 2025, ...

Halozyme Therapeutics, Inc.: Halozyme Reports Full Year 2025 Record Revenue Of $1.4 Billion And Reiterates Strong 2026 Financial Guidance

Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billionFull Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million Completed Acquisitions ...